GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprea Therapeutics Inc (NAS:APRE) » Definitions » Current Ratio

Aprea Therapeutics (Aprea Therapeutics) Current Ratio : 5.13 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Aprea Therapeutics Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Aprea Therapeutics's current ratio for the quarter that ended in Dec. 2023 was 5.13.

Aprea Therapeutics has a current ratio of 5.13. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Aprea Therapeutics's Current Ratio or its related term are showing as below:

APRE' s Current Ratio Range Over the Past 10 Years
Min: 5.13   Med: 7.73   Max: 14.68
Current: 5.13

During the past 7 years, Aprea Therapeutics's highest Current Ratio was 14.68. The lowest was 5.13. And the median was 7.73.

APRE's Current Ratio is ranked better than
61.84% of 1554 companies
in the Biotechnology industry
Industry Median: 3.77 vs APRE: 5.13

Aprea Therapeutics Current Ratio Historical Data

The historical data trend for Aprea Therapeutics's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprea Therapeutics Current Ratio Chart

Aprea Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
Get a 7-Day Free Trial 14.68 6.03 7.73 9.42 5.13

Aprea Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.42 7.57 7.25 6.15 5.13

Competitive Comparison of Aprea Therapeutics's Current Ratio

For the Biotechnology subindustry, Aprea Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aprea Therapeutics's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aprea Therapeutics's Current Ratio distribution charts can be found below:

* The bar in red indicates where Aprea Therapeutics's Current Ratio falls into.



Aprea Therapeutics Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Aprea Therapeutics's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=22.521/4.386
=5.13

Aprea Therapeutics's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=22.521/4.386
=5.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aprea Therapeutics  (NAS:APRE) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Aprea Therapeutics Current Ratio Related Terms

Thank you for viewing the detailed overview of Aprea Therapeutics's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Aprea Therapeutics (Aprea Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
3805 Old Easton Road, Doylestown, PA, USA, 18902
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).
Executives
Jean-pierre Bizzari director 235 LAUREL LN, HAVERFOLD PA 19041
Bernd R. Seizinger director 535 BOYLSTON STREET, BOSTON MA 02116
Gabriela Gruia director C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
John P. Hamill officer: SrVP/CFO/Prin. Fin &Acctg. Off 4092 NEW HOPE ROAD, FURLONG PA 18925
Michael Grissinger director C/O RESTORBIO, INC., 500 BOYLSTON ST., 12TH FLOOR, BOSTON MA 02116
Marc Duey director 27 STRATHMORE ROAD, NATICK MA 01760
Oren Gilad officer: President, CEO 535 BOYLSTON STREET, BOSTON MA 02116
Rifat Pamukcu director 535 BOYLSTON STREET, BOSTON MA 02116
Christian S Schade director, officer: President & CEO MEDAREX, 707 STATE ROAD, PRINCETON NJ 08540
Eyal C. Attar officer: SVP, Chief Medical Officer 535 BOYLSTON STREET, BOSTON MA 02116
Gregory Alan Korbel officer: Chief Business Officer 535 BOYLSTON STREET, BOSTON MA 02116
Lars B. Abrahmsen officer: SVP, Chief Scientific Officer 535 BOYLSTON STREET, BOSTON MA 02116
Jeremy Green 10 percent owner 45 W. 27TH STREET, FLOOR 11, NEW YORK NY 10001
Redmile Group, Llc 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
5am Ventures Iv, L.p. 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107

Aprea Therapeutics (Aprea Therapeutics) Headlines

From GuruFocus

Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split

By sperokesalga sperokesalga 02-13-2023

Aprea Therapeutics Appoints John Hamill as Chief Financial Officer

By Stock market mentor Stock market mentor 01-30-2023

Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference

By sperokesalga sperokesalga 06-14-2023